{"title":"Vectors \u0026 Viruses","description":"","products":[{"product_id":"aav-null-aav-serotype-1-bhv21500001","title":"AAV-Null (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500001\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020164915565,"sku":"SL100802-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020164948333,"sku":"SL100802-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500001_aav-null-aav-serotype-1_SL100802.jpg?v=1770796172"},{"product_id":"aav-gfp-aav-serotype-1-bhv21500002","title":"AAV-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500002\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020164981101,"sku":"SL100803-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165013869,"sku":"SL100803-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500002_aav-gfp-aav-serotype-1_SL100803.png?v=1770796172"},{"product_id":"scaav-gfp-aav-serotype-1-self-complementary-bhv21500003","title":"scAAV-GFP (AAV Serotype 1, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500003\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165046637,"sku":"SL100803-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165079405,"sku":"SL100803-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500003_scaav-gfp-aav-serotype-1-self-complementary_SL100803-SC.png?v=1770796172"},{"product_id":"aav-cre-aav-serotype-1-bhv21500004","title":"AAV-Cre (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500004\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165112173,"sku":"SL100804-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165144941,"sku":"SL100804-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500004_aav-cre-aav-serotype-1_SL100804.png?v=1770796172"},{"product_id":"scaav-cre-aav-serotype-1-self-complementary-bhv21500005","title":"scAAV-Cre (AAV Serotype 1, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500005\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165177709,"sku":"SL100804-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165210477,"sku":"SL100804-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500005_scaav-cre-aav-serotype-1-self-complementary_SL100804-SC.png?v=1770796173"},{"product_id":"aav-cre-gfp-aav-serotype-1-bhv21500006","title":"AAV-Cre-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500006\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165243245,"sku":"SL100805-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165276013,"sku":"SL100805-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500006_aav-cre-gfp-aav-serotype-1_SL100805.png?v=1770796173"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-1-bhv21500007","title":"AAV-U6-shRNA(Scramble)-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(Scramble)-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500007\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165308781,"sku":"SL100806-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165341549,"sku":"SL100806-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500007_aav-u6-shrna-scramble-gfp-aav-serotype-1_SL100806.png?v=1770796174"},{"product_id":"aav-cag-gfp-aav-serotype-1-bhv21500008","title":"AAV-CAG-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500008\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165374317,"sku":"SL100807-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165407085,"sku":"SL100807-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500008_aav-cag-gfp-aav-serotype-1_SL100807.png?v=1770796174"},{"product_id":"aav-synapsin-gfp-aav-serotype-1-bhv21500009","title":"AAV-Synapsin-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500009\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165439853,"sku":"SL100808-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165472621,"sku":"SL100808-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500009_aav-synapsin-gfp-aav-serotype-1_SL100808.png?v=1770796174"},{"product_id":"scaav-synapsin-gfp-aav-serotype-1-self-complementary-bhv21500010","title":"scAAV-Synapsin-GFP (AAV Serotype 1, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500010\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165505389,"sku":"SL100808-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165538157,"sku":"SL100808-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500010_scaav-synapsin-gfp-aav-serotype-1-self-complementary_SL100808-SC.png?v=1770796175"},{"product_id":"aav-mrfp-aav-serotype-1-bhv21500011","title":"AAV-mRFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-mRFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500011\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003emRFP is the encoded payload for this construct. A \u003cstrong\u003emRFP + RFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mRFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165570925,"sku":"SL100809-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165603693,"sku":"SL100809-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500011_aav-mrfp-aav-serotype-1_SL100809.png?v=1770796175"},{"product_id":"aav-null-aav-serotype-2-bhv21500012","title":"AAV-Null (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500012\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165636461,"sku":"SL100811-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165669229,"sku":"SL100811-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500012_aav-null-aav-serotype-2_SL100811.jpg?v=1770796175"},{"product_id":"aav-gfp-aav-serotype-2-bhv21500013","title":"AAV-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500013\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165701997,"sku":"SL100812-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165734765,"sku":"SL100812-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500013_aav-gfp-aav-serotype-2_SL100812.png?v=1770796176"},{"product_id":"scaav-gfp-aav-serotype-2-self-complementary-bhv21500014","title":"scAAV-GFP (AAV Serotype 2, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500014\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165767533,"sku":"SL100812-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165800301,"sku":"SL100812-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500014_scaav-gfp-aav-serotype-2-self-complementary_SL100812-SC.png?v=1770796176"},{"product_id":"aav-cre-aav-serotype-2-bhv21500015","title":"AAV-Cre (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500015\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165833069,"sku":"SL100813-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165865837,"sku":"SL100813-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500015_aav-cre-aav-serotype-2_SL100813.png?v=1770796176"},{"product_id":"scaav-cre-aav-serotype-2-self-complementary-bhv21500016","title":"scAAV-Cre (AAV Serotype 2, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500016\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165898605,"sku":"SL100813-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165931373,"sku":"SL100813-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500016_scaav-cre-aav-serotype-2-self-complementary_SL100813-SC.png?v=1770796176"},{"product_id":"aav-cre-gfp-aav-serotype-2-bhv21500017","title":"AAV-Cre-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500017\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165964141,"sku":"SL100814-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165996909,"sku":"SL100814-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500017_aav-cre-gfp-aav-serotype-2_SL100814.png?v=1770796177"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-2-bhv21500018","title":"AAV-U6-shRNA(scramble)-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(scramble)-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500018\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166029677,"sku":"SL100815-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166062445,"sku":"SL100815-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500018_aav-u6-shrna-scramble-gfp-aav-serotype-2_SL100815.png?v=1770796177"},{"product_id":"aav-cag-gfp-aav-serotype-2-bhv21500019","title":"AAV-CAG-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500019\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166095213,"sku":"SL100816-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166127981,"sku":"SL100816-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500019_aav-cag-gfp-aav-serotype-2_SL100816.png?v=1770796178"},{"product_id":"aav-synapsin-gfp-aav-serotype-2-bhv21500020","title":"AAV-Synapsin-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500020\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166160749,"sku":"SL100817-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166193517,"sku":"SL100817-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500020_aav-synapsin-gfp-aav-serotype-2_SL100817.png?v=1770796178"},{"product_id":"scaav-synapsin-gfp-aav-serotype-2-self-complementary-bhv21500021","title":"scAAV-Synapsin-GFP (AAV Serotype 2, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500021\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166226285,"sku":"SL100817-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166259053,"sku":"SL100817-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500021_scaav-synapsin-gfp-aav-serotype-2-self-complementary_SL100817-SC.png?v=1770796178"},{"product_id":"aav-null-aav-serotype-5-bhv21500022","title":"AAV-Null (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500022\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/5 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166291821,"sku":"SL100818-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166324589,"sku":"SL100818-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500022_aav-null-aav-serotype-5_SL100818.jpg?v=1770796179"},{"product_id":"aav-gfp-aav-serotype-5-bhv21500023","title":"AAV-GFP (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500023\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/5 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166357357,"sku":"SL100819-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166390125,"sku":"SL100819-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500023_aav-gfp-aav-serotype-5_SL100819.png?v=1770796179"},{"product_id":"scaav-gfp-aav-serotype-5-self-complementary-bhv21500024","title":"scAAV-GFP (AAV Serotype 5, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500024\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/5 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166422893,"sku":"SL100819-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166455661,"sku":"SL100819-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500024_scaav-gfp-aav-serotype-5-self-complementary_SL100819-SC.png?v=1770796179"},{"product_id":"aav-cre-aav-serotype-5-bhv21500025","title":"AAV-Cre (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500025\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/5).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166488429,"sku":"SL100820-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166521197,"sku":"SL100820-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500025_aav-cre-aav-serotype-5_SL100820.png?v=1770796180"},{"product_id":"scaav-cre-aav-serotype-5-self-complementary-bhv21500026","title":"scAAV-Cre (AAV Serotype 5, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500026\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/5).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166553965,"sku":"SL100820-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166586733,"sku":"SL100820-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500026_scaav-cre-aav-serotype-5-self-complementary_SL100820-SC.png?v=1770796180"},{"product_id":"aav-cre-gfp-aav-serotype-5-bhv21500027","title":"AAV-Cre-GFP (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500027\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/5).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166619501,"sku":"SL100821-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166652269,"sku":"SL100821-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500027_aav-cre-gfp-aav-serotype-5_SL100821.png?v=1770796180"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-5-bhv21500028","title":"AAV-U6-shRNA(scramble)-GFP (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(scramble)-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500028\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166685037,"sku":"SL100822-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166717805,"sku":"SL100822-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500028_aav-u6-shrna-scramble-gfp-aav-serotype-5_SL100822.png?v=1770796181"},{"product_id":"aav-cag-gfp-aav-serotype-5-bhv21500029","title":"AAV-CAG-GFP (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500029\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/5 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166750573,"sku":"SL100823-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166783341,"sku":"SL100823-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500029_aav-cag-gfp-aav-serotype-5_SL100823.png?v=1770796181"},{"product_id":"aav-synapsin-gfp-aav-serotype-5-bhv21500030","title":"AAV-Synapsin-GFP (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500030\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/5 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166816109,"sku":"SL100824-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166848877,"sku":"SL100824-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500030_aav-synapsin-gfp-aav-serotype-5_SL100824.png?v=1770796181"},{"product_id":"scaav-synapsin-gfp-aav-serotype-5-self-complementary-bhv21500031","title":"scAAV-Synapsin-GFP (AAV Serotype 5, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500031\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/5 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166881645,"sku":"SL100824-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166914413,"sku":"SL100824-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500031_scaav-synapsin-gfp-aav-serotype-5-self-complementary_SL100824-SC.png?v=1770796182"},{"product_id":"aav-null-aav-serotype-6-bhv21500032","title":"AAV-Null (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500032\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/6 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166947181,"sku":"SL100825-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166979949,"sku":"SL100825-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500032_aav-null-aav-serotype-6_SL100825.jpg?v=1770796182"},{"product_id":"aav-gfp-aav-serotype-6-bhv21500033","title":"AAV-GFP (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500033\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/6 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167012717,"sku":"SL100826-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167045485,"sku":"SL100826-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500033_aav-gfp-aav-serotype-6_SL100826.png?v=1770796182"},{"product_id":"scaav-gfp-aav-serotype-6-self-complementary-bhv21500034","title":"scAAV-GFP (AAV Serotype 6, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500034\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/6 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167078253,"sku":"SL100826-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167111021,"sku":"SL100826-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500034_scaav-gfp-aav-serotype-6-self-complementary_SL100826-SC.png?v=1770796183"},{"product_id":"aav-cre-aav-serotype-6-bhv21500035","title":"AAV-Cre (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500035\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/6).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167143789,"sku":"SL100827-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167176557,"sku":"SL100827-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500035_aav-cre-aav-serotype-6_SL100827.png?v=1770796183"},{"product_id":"scaav-cre-aav-serotype-6-self-complementary-bhv21500036","title":"scAAV-Cre (AAV Serotype 6, Self-complementary )","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500036\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/6).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167209325,"sku":"SL100827-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167242093,"sku":"SL100827-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500036_scaav-cre-aav-serotype-6-self-complementary_SL100827-SC.png?v=1770796183"},{"product_id":"aav-cre-gfp-aav-serotype-6-bhv21500037","title":"AAV-Cre-GFP (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500037\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/6).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167274861,"sku":"SL100828-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167307629,"sku":"SL100828-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500037_aav-cre-gfp-aav-serotype-6_SL100828.png?v=1770796184"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-6-bhv21500038","title":"AAV-U6-shRNA(Scramble)-GFP (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(Scramble)-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500038\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167340397,"sku":"SL100829-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167373165,"sku":"SL100829-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500038_aav-u6-shrna-scramble-gfp-aav-serotype-6_SL100829.png?v=1770796184"},{"product_id":"aav-cag-gfp-aav-serotype-6-bhv21500039","title":"AAV-CAG-GFP (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500039\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/6 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167438701,"sku":"SL100830-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167471469,"sku":"SL100830-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500039_aav-cag-gfp-aav-serotype-6_SL100830.png?v=1770796185"},{"product_id":"aav-synapsin-gfp-aav-serotype-6-bhv21500040","title":"AAV-Synapsin-GFP (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500040\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/6 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167569773,"sku":"SL100831-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167602541,"sku":"SL100831-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500040_aav-synapsin-gfp-aav-serotype-6_SL100831.png?v=1770796185"},{"product_id":"scaav-synapsin-gfp-aav-serotype-6-self-complementary-bhv21500041","title":"scAAV-Synapsin-GFP (AAV Serotype 6, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500041\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/6 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167635309,"sku":"SL100831-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167668077,"sku":"SL100831-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500041_scaav-synapsin-gfp-aav-serotype-6-self-complementary_SL100831-SC.png?v=1770796185"},{"product_id":"aav-null-aav-serotype-8-bhv21500042","title":"AAV-Null (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500042\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167700845,"sku":"SL100832-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167733613,"sku":"SL100832-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500042_aav-null-aav-serotype-8_SL100832.jpg?v=1770796185"},{"product_id":"aav-gfp-aav-serotype-8-bhv21500043","title":"AAV-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500043\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167766381,"sku":"SL100833-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167799149,"sku":"SL100833-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500043_aav-gfp-aav-serotype-8_SL100833.png?v=1770796186"},{"product_id":"scaav-gfp-aav-serotype-8-self-complementary-bhv21500044","title":"scAAV-GFP (AAV Serotype 8, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500044\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167831917,"sku":"SL100833-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167864685,"sku":"SL100833-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500044_scaav-gfp-aav-serotype-8-self-complementary_SL100833-SC.png?v=1770796186"},{"product_id":"aav-cre-aav-serotype-8-bhv21500045","title":"AAV-Cre (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500045\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167897453,"sku":"SL100834-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167930221,"sku":"SL100834-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500045_aav-cre-aav-serotype-8_SL100834.png?v=1770796186"},{"product_id":"scaav-cre-aav-serotype-8-self-complementary-bhv21500046","title":"scAAV-Cre (AAV Serotype 8, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500046\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167962989,"sku":"SL100834-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167995757,"sku":"SL100834-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500046_scaav-cre-aav-serotype-8-self-complementary_SL100834-SC.png?v=1770796187"},{"product_id":"aav-cre-gfp-aav-serotype-8-bhv21500047","title":"AAV-Cre-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500047\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168028525,"sku":"SL100835-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168061293,"sku":"SL100835-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500047_aav-cre-gfp-aav-serotype-8_SL100835.png?v=1770796187"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-8-bhv21500048","title":"AAV-U6-shRNA(scramble)-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(scramble)-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500048\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168094061,"sku":"SL100836-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168126829,"sku":"SL100836-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500048_aav-u6-shrna-scramble-gfp-aav-serotype-8_SL100836.png?v=1770796187"},{"product_id":"aav-cag-gfp-aav-serotype-8-bhv21500049","title":"AAV-CAG-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500049\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168159597,"sku":"SL100837-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168192365,"sku":"SL100837-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500049_aav-cag-gfp-aav-serotype-8_SL100837.png?v=1770796188"},{"product_id":"aav-synapsin-gfp-aav-serotype-8-bhv21500050","title":"AAV-Synapsin-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n  \u003cdiv class=\"product-hero-large\"\u003e\n    \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n    \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n    \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n    \u003cp class=\"hero-sku-large\"\u003eBHV21500050\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eResearch Background\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n      \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003csection class=\"detail-section-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cdiv class=\"feature-grid-large\"\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n          \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n          \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n        \u003c\/div\u003e\n        \u003cdiv class=\"feature-item-large\"\u003e\n          \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n          \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\n  \u003cdiv class=\"two-column-large\"\u003e\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-green\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n\n    \u003csection class=\"detail-section-large compact\"\u003e\n      \u003cdiv class=\"section-header-large\"\u003e\n        \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n          \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n            \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n          \u003c\/svg\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n      \u003c\/div\u003e\n      \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n    \u003c\/section\u003e\n  \u003c\/div\u003e\n\n  \u003csection class=\"detail-section-large highlight-large\"\u003e\n    \u003cdiv class=\"section-header-large\"\u003e\n      \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n        \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n          \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n        \u003c\/svg\u003e\n      \u003c\/div\u003e\n      \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"section-body-large\"\u003e\n      \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n  .product-detail-large {\n    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n    color: #1e293b;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 2rem;\n    font-size: 1.5rem;\n  }\n  .product-hero-large {\n    text-align: center;\n    padding: 3rem 2rem;\n    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n    border-radius: 16px;\n    margin-bottom: 3rem;\n    border: 2px solid #e2e8f0;\n  }\n  .hero-badge-large {\n    display: inline-block;\n    background: #3b82f6;\n    color: white;\n    padding: 0.5rem 1.5rem;\n    border-radius: 30px;\n    font-size: 1.25rem;\n    font-weight: 700;\n    margin-bottom: 1rem;\n  }\n  .hero-title-large {\n    font-size: 3rem;\n    font-weight: 800;\n    color: #0f172a;\n    margin: 0 0 1rem 0;\n  }\n  .hero-subtitle-large {\n    font-size: 1.75rem;\n    color: #64748b;\n    margin: 0;\n    font-weight: 500;\n  }\n  .detail-section-large {\n    background: white;\n    border-radius: 16px;\n    padding: 2.5rem;\n    margin-bottom: 2.5rem;\n    border: 2px solid #e2e8f0;\n  }\n  .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n  .detail-section-large.highlight-large {\n    background: #f8fafc;\n    border-left: 6px solid #14b8a6;\n  }\n  .section-header-large {\n    display: flex;\n    align-items: center;\n    gap: 1.25rem;\n    margin-bottom: 1.5rem;\n    padding-bottom: 1.25rem;\n    border-bottom: 2px solid #f1f5f9;\n  }\n  .section-icon-large {\n    width: 4rem;\n    height: 4rem;\n    border-radius: 12px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    flex-shrink: 0;\n  }\n  .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n  .bg-blue { background: #3b82f6; }\n  .bg-purple { background: #8b5cf6; }\n  .bg-green { background: #10b981; }\n  .bg-orange { background: #f59e0b; }\n  .bg-teal { background: #14b8a6; }\n  .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n  .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n  .section-body-large p:last-child { margin-bottom: 0; }\n  .section-body-large strong { color: #0f172a; font-weight: 700; }\n  .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n  .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n  .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n  .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n  .check-list-large { list-style: none; padding: 0; margin: 0; }\n  .check-list-large li {\n    padding: 1rem 0 1rem 3rem;\n    position: relative;\n    font-size: 1.5rem;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n    line-height: 1.5;\n  }\n  .check-list-large li:last-child { border-bottom: none; }\n  .check-list-large li::before {\n    content: \"✓\";\n    position: absolute;\n    left: 0;\n    color: #10b981;\n    font-weight: 800;\n    font-size: 2rem;\n    top: 0.875rem;\n  }\n  .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n  .bullet-list-large li {\n    padding: 1rem 0 1rem 2.5rem;\n    position: relative;\n    font-size: 1.5rem;\n    line-height: 1.6;\n    color: #334155;\n    border-bottom: 2px solid #f8fafc;\n  }\n  .bullet-list-large li:last-child { border-bottom: none; }\n  .bullet-list-large li::before {\n    content: \"•\";\n    position: absolute;\n    left: 0;\n    color: #f59e0b;\n    font-weight: 900;\n    font-size: 2.5rem;\n    line-height: 1;\n    top: 0.5rem;\n  }\n  @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n  @media (max-width: 768px) {\n    .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n    .hero-title-large { font-size: 2.25rem; }\n    .hero-subtitle-large { font-size: 1.5rem; }\n    .detail-section-large h3 { font-size: 1.875rem; }\n    .section-body-large p, .feature-item-large p,\n    .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n    .detail-section-large { padding: 1.75rem; }\n  }\n\n  .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168225133,"sku":"SL100838-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168257901,"sku":"SL100838-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500050_aav-synapsin-gfp-aav-serotype-8_SL100838.png?v=1770796188"}],"url":"https:\/\/www.ebiohippo.com\/collections\/vectors-viruses.oembed","provider":"BioHippo","version":"1.0","type":"link"}